Results 171 to 180 of about 156,533 (274)
Radiotherapy for Hypopharyngeal Carcinoma: Analysis of Multi-institutional Data From Over 170 Patients. [PDF]
Yamazaki H +13 more
europepmc +1 more source
The organic nanozyme IR‐IHpd, which has NIR‐PDT and POD‐like activity, is designed for continuous ROS generation. It is co‐encapsulated with CB‐839 and coated with DC membranes to simultaneously target tumors and T cells. Under NIR irradiation, immunogenic cell death is activated. Concurrently, CB‐839 suppresses ammonia‐induced T lymphocyte death (AITD)
Meng Suo +7 more
wiley +1 more source
Analysis of efficacy and safety of intensity-modulated radiotherapy with "Target-Ring" strategy for stage IVA large-volume thymoma and thymic carcinoma: a single-center study. [PDF]
Chang D +7 more
europepmc +1 more source
A programmable nanoreactor was engineered for precise cGAS‐STING pathway activation in cancer immunotherapy. This strategy bridges targeted tumor DNA damage with DC immunomodulation, providing a translatable platform to unlock innate and adaptive antitumor immunity.
Shuang Liang +14 more
wiley +1 more source
Clinical application of cone beam CT in intensity-modulated radiotherapy for the moderate to severe thyroid-associated ophthalmopathy. [PDF]
Kang D, Hu H, Ma S, Bin S.
europepmc +1 more source
A universal ROR1 antibody‐engineered lipid nanoparticle (LNP) is constructed by sequential drug encapsulation and antibody conjugation. The LNP not only enables enhanced chemotherapeutic efficiency by targeting drug delivery and precise localization of deep‐seated tumors through NIR‐II fluorescence imaging, but also remodels immunosuppressive TME ...
Yeneng Dai +12 more
wiley +1 more source
Comparison of adverse events between intensity-modulated radiation therapy and tomotherapy for early stage breast cancer: a retrospective cohort study. [PDF]
Xia Y +12 more
europepmc +1 more source
This study developed a novel drug delivery platform that overcomes the blood‐brain barrier in glioblastoma. By fusing IGFBP7 with small extracellular vesicles, the platform specifically targets tumor vasculature. It effectively delivers temozolomide, suppressing tumor growth at low doses.
Lingling Liu +17 more
wiley +1 more source
Rational Radionuclide Therapy for Recurrent Meningioma. [PDF]
Chen WC, Raleigh DR.
europepmc +1 more source
This research provides the first comprehensive evidence that PS‐MPs exacerbate ccRCC progression by activating the NF‐κB and TGF‐β pathways. These findings establish PS‐MPs as an environmental risk factor for ccRCC progression and identify the NF‐κB and TGF‐β signaling as potential therapeutic targets to mitigate the adverse effects of ‐PS‐MPs exposure.
Shiqi Ye +18 more
wiley +1 more source

